Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene glycol loxenatide versus insulin glargine for early renal protection in newly diagnosed type 2 diabetes
ChiCTR2100046845Phase 4Recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of polyethylene glycol loxenatide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Non-invasive quantitative fat measurement of pancreas, kidneys, and other organs, Kidney tissue oxygenation status and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
polyethylene glycol loxenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100046845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046845.